Market News

Wasatch Advisors Has Lowered Esperion Therapeutics (ESPR) Position By $2.12 Million; Temasek Holdings Private LTD Has Upped By $5.84 Million Its Regeneron Pharmaceuticals (REGN) Holding

Temasek Holdings Private Ltd increased Regeneron Pharmaceuticals (REGN) stake by 7.36% reported in 2017Q3 SEC filing. Temasek Holdings Private Ltd acquired 13,068 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Temasek Holdings Private Ltd holds 190,621 shares with $85.23 million value, up from 177,553 last quarter. Regeneron Pharmaceuticals now has $34.14 billion valuation. The stock decreased 1.77% or $5.727 during the last trading session, reaching $317.313. About 408,136 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 21, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Wasatch Advisors Inc decreased Esperion Therapeutics Inc. (ESPR) stake by 5.6% reported in 2017Q3 SEC filing. Wasatch Advisors Inc sold 42,311 shares as Esperion Therapeutics Inc. (ESPR)’s stock rose 33.24%. The Wasatch Advisors Inc holds 713,404 shares with $35.76M value, down from 755,715 last quarter. Esperion Therapeutics Inc. now has $2.08 billion valuation. The stock increased 4.92% or $3.73 during the last trading session, reaching $79.52. About 448,037 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 21, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Wasatch Advisors Inc increased Smartfinancial Inc. stake by 33,330 shares to 114,330 valued at $2.75 million in 2017Q3. It also upped Blue Hills Bancorp Inc. (NASDAQ:BHBK) stake by 24,898 shares and now owns 129,000 shares. Computer Programs & Systems In (NASDAQ:CPSI) was raised too.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics had 53 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, February 26 by Chardan Capital Markets. The firm has “Buy” rating given on Wednesday, June 29 by Citigroup. The rating was downgraded by Barclays Capital to “Equal-Weight” on Wednesday, June 29. On Wednesday, June 29 the stock rating was downgraded by Credit Suisse to “Underperform”. Bank of America upgraded Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Friday, January 5 to “Buy” rating. The rating was downgraded by Zacks to “Hold” on Friday, September 4. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm has “Buy” rating given on Wednesday, October 18 by Cowen & Co. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, February 25 report. The stock has “Buy” rating by Lake Street on Wednesday, June 29.

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.45, from 1.22 in 2017Q2. It is positive, as 11 investors sold ESPR shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Fmr Llc reported 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). California State Teachers Retirement Systems has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Aqr Cap Management Ltd Co holds 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 103,726 shares. Iguana Mngmt Ltd Limited Liability Company invested in 150,000 shares or 4.2% of the stock. Meeder Asset Mgmt has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 257 shares. Parametric Portfolio Associate Limited Liability Corporation accumulated 49,335 shares or 0% of the stock. Wells Fargo And Company Mn owns 14,519 shares for 0% of their portfolio. 235,889 are owned by Lord Abbett & Co Ltd Liability Co. State Bank Of Ny Mellon holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 115,372 shares. Nationwide Fund Advisors stated it has 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Ubs Asset Mgmt Americas has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). State Common Retirement Fund owns 15,900 shares. Wellington Llp owns 31,159 shares or 0% of their US portfolio. St Johns Invest Mngmt Limited Liability Com owns 0.01% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 260 shares. Ameriprise Financial accumulated 0% or 24,913 shares.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 earnings per share, down 39.53% or $0.51 from last year’s $-1.29 per share. After $-1.86 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.23% EPS growth.

Since August 22, 2017, it had 0 insider buys, and 5 insider sales for $2.48 million activity. 663 shares valued at $330,574 were sold by Landry Robert E on Friday, September 1. $80.03 million worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was bought by Sanofi on Wednesday, August 23. $900,000 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by BAKER CHARLES A on Friday, September 29. Another trade for 1,500 shares valued at $712,500 was made by BROWN MICHAEL S on Thursday, October 5. 1,000 shares valued at $325,600 were sold by GOLDSTEIN JOSEPH L on Friday, February 9.

Leave a Reply

Your email address will not be published. Required fields are marked *